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Sllmmary 
Antigen-specific T cell activation requires the engagement of the T cell receptor (TCR) with 
antigen as well as the engagement of appropriate costimulatory molecules. The most extensively 
characterized  pathway of costimulation has been that involving the interaction of CD28 and 
CTLA4 on the T cell with B7 (now termed B7-1) on antigen presenting cells. Recently, B7-2 
a second costimulatory ligand for CTLA4, was described, demonstrating the potential complexity 
of costimulatory interactions. This report examines and compares the expression and function 
of B7-1 and B7-2. Overall these results indicate that (a) B7-1 and B7-2 can be expressed by multiple 
cell types, including B cells, T cells, macrophages, and dendritic cells, all of which are therefore 
candidate populations for delivering costimulatory signals  mediated by these molecules; (b) 
stimulating B cells with either LPS or anti-IgD-dextran induced expression of both B7-1 and 
B7-2,  and peak expression of both costimulatory molecules occurred after 18-42 h of culture. 
Expression of B7-2 on these B cell populations was significantly higher than expression of B7-1 
at all times assayed after stimulation; (c) blocking of B7-2 costimulatory activity inhibited TCg- 
dependent T  cell proliferation and cytokine production, without affecting early consequences 
of TCR signaling such as induction of CD69 or interleukin 2 receptor ot (IL-2Ro~); and (d) 
expression of B7-1 and of B7-2 can be regulated by a variety of stimuli. Moreover,  expression 
of B7-1 and B7-2 can be independently regulated by the same stimulus, providing an additional 
complexity in the mechanisms available for regulating costimulation and hence immune response. 
ctivation of T cells to cytokine production and prolifera- 
tion requires  at least two distinct signals (1, 2). The 
antigen-specific "first signal" is provided when the TCR in- 
teracts  with antigen presented in the context of MHC ex- 
pressed on APCs. The "second signal" or costimulatory signal 
is provided by a set of receptor-ligand interactions distinct 
from the TCR interactions.  In both mice and humans, CD28 
has been identified as one of the molecules on T cells through 
which costimulatory signals can be delivered (2-7). CTLA4 
is a molecule expressed on T cells that may also be involved 
in APC-dependent T cell activation as suggested by the fact 
that a soluble CTLA4 fusion protein (CTLA4Ig)  1 inhibits 
costimulatory signaling (8-10).  B7 (now termed B7-1),  a 
1 Abbreviations used in this paper: CHO, Chinese  hamster  ovary; CTLA4Ig, 
soluble fusion protein of  CTLA; FCM, flow cytometry; HPKT, 
h~thine-guanine phosphoribosyi  transferase;  PEC, peritoneal  exudate 
macrophages;  R, receptor;  Tg, transgenic;  TRA, Texas  Red streptavidin. 
ligand for both CD28 and CTLA4, is expressed by APCs 
and has been shown to be capable of delivering a costimula- 
tory signal (4, 8, 11-14). Recently, we reported the existence 
of B7-2, a second CTLA4 ligand expressed on murine B cells 
and defined by the mAb GL1, which provides costimulatory 
function both in vitro and in vivo for APC-dependent T cell 
activation (15-17). 
B7-1 and B7-2, members of the immunoglobulin super- 
gene family, are encoded by separate genes, and both mole- 
cules can provide costimulatory function (6, 12, 15-20). APCs 
derived from mice in which the gene encoding B7-1 has been 
inactivated by homologous recombination express B7-2 and 
are competent to present alloantigens (16). As was previously 
demonstrated for B7-1 transfectants,  B7-2 transfectants are 
capable of providing costimulatory signals for antigen acti- 
vated T cells (17). Taken together, these results demonstrate 
the existence of two distinct costimulatory molecules, each 
of which can provide costimulatory signals. It is unknown 
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by B7-1 and B7-2 are functionally distinct  or overlapping. 
In this report, expression of B7-2 and B7-1 was analyzed 
on freshly explanted as well as activated cultures of murine 
B  cells,  T  cells,  and  thioglycollate-induced peritoneal exu- 
date macrophages  (PEC).  Further,  we examined the func- 
tion of B7-1 and B7-2 molecules on APC-dependent T  cell 
activation.  The functional implications  of the existence of 
multiple costimulatory molecules in T cell activation are dis- 
cussed. 
Materials  and Methods 
Animals.  Female  DBA/2,  BALB/c,  B10.A,  CBA/J,  and 
CBA/CaH mice were obtained from Frederick Cancer Research 
Center (Frederick, MD). T cell receptor V~8.1 transgenic (V~8.1 
Tg) mice were generously provided by Dr. Mark Greene (Univer- 
sity of Pennsylvania, Philadelphia,  PA) (21). BALB.Mls  ' mice were 
generated by Bernmen et al. (22). All mice were used at 3-12 mo 
of age. 
Preparation and Culture of Cell Suspensions.  Single cell suspen- 
sions were prepared from spleens, and erythrocytes were lysed as 
previously described (23).  T  cell-depleted B cell-enriched APCs 
were prepared by treating spleen cells with anti-Thy-l.2 +  C and 
cuhured in vitro at 2-4  x  10  ~ cells/ml. B cells were stimulated 
in vitro with LPS (Sigma Chemical Co., St. Louis, MO) (15/~g/ml), 
IL-5 (104 U/ml), or anti-IgD-dextran (mouse mAb H/~ffl) (0.01 
/~g/ml) (24) generously provided by Dr. James Mond (Uniformed 
Services University of the Health Sciences, Bethesda, MD). Viable 
cultured cells were enriched by isolation on a Lymphocyte Separa- 
tion Medium (Organon Teknika Corp., Durham, NC) gradient. 
PECs were collected by peritoneal lavage 3-5 d after injection 
of 3% thioglycollate medium intraperitoneal (National Institutes 
of Health [NIH] Media Unit) (25). This cell preparation was >90% 
CD11b/MAC-1 + and contained >80% latex bead ingesting mac- 
rophages (26).  PECs were cuhured for 18 h  (37~  humidified 
COs incubator) on dishes  from Falcon  Labware  (1029; Lincoln 
Park,  NJ) in the presence or absence of either 15/~g/ml LPS or 
100 U/ml recombinant IFN-'), (Genetec, South San Francisco, CA) 
and adherent cells were collected using trypsin-versine solution 
(Biofluids,  Inc., RockviUe,  MD). 
Chinese hamster ovary (CHO) cells transfected with the gene 
encoding murine B7-1 have previously been described (6). 
T cells were enriched by passage over tissue culture plates that 
had been coated with rabbit anti-mouse-IgG (Organon Teknika 
Corp.). T cells were stimulated either with 4/~g/ml soluble anti- 
CD3e (145-2Cll mAb, hamster Ig, American Type Culture Col- 
lection [ATCC]  CTLL-1975) (27) presented by syngeneic APC or 
with Mls ~ expressing  APC. Va8.1 Tg (Mls ' specific) T cells were 
stimulated  with  titrated numbers  of APC isolated  from either 
CBA/J (H-2  k, Mls'-positive) or CBA/CaH (H-2  ~, Mls'-negative) 
mice that had been injected with 200/~1 i.p. goat anti-IgD serum 
24  h  before harvest  (28).  Alternatively,  BALB/c  (H-2  a,  Mlg- 
negative) T cells were stimulated with titrated numbers of APCs 
isohted from either BALB/c.Mls' (H-2  a, Mls'-positive)  or BALB/c 
mice that had been injected with goat anti-IgD serum. Goat anti- 
IgD serum was the kind gift of Dr. Fred Finkelman (Uniformed 
Services University of the Health Sciences). APCs were prepared 
from T-depleted spleen cells and were inactivated by mitomycin C 
treatment (Sigma Chemical Co.). For proliferation assays, T cells 
were cocultured in 96-well plates in the presence or absence of in- 
hibitory mAb and titrated numbers of mitomycin C-treated APCs. 
For PCR analysis and cytokine assays, equal numbers of T  cells 
and APCs were cocuhured with the indicated mAb. Cultures in- 
tended for cytokine analysis were generated in the presence of 0.1% 
anti-IL-2 receptor (R) oe ascites (7D4 mAb, rat IgM, ATCC CRD 
1698) (29) and collected at the indicated times. Cells were harvested 
at 24 h for examination of activation markers (CD69 and Ib2R~) 
and were harvested at 60 or 84 h for proliferation assays. For prolifer- 
ation assays, cells were labeled with 1 #Ci of 3H during the final 
15 h of the culture period. 
Reagents.  All antibodies were pretitrated and used at saturating 
amounts for flow cytometric studies.  GL1 (anti-B7-2,  rat IgG2a) 
(15) and FD441.8 (anti-LFA-1,  rat IgG2b, ATCC TIB 213) (30) 
mAb were purified from culture supernatants using goat anti-rat 
IgG agarose columns (Sigma Chemical Co.). RA3-6B2 (31) is a 
CD45-spedfic rat IgG2a mAb that reacts with essentially all B lym- 
phocytes, but with very few T lymphocytes (anti-B220).  Purified-, 
FITC-, and biotin-RA3-6B2 were purchased from PharMingen (San 
Diego, CA) as were purified mAb 1G10 (anti-B7-1, rat IgG2a) (32), 
biotin-3C7 (anti-Ib2Kc~, rat IgG2a) (29), biotin-H1 (anti-CD69, 
hamster IgG)  (33),  and FITC-M1/70  (anti-CD11b/MAB-1,  rat 
IgG2b) (34). Biotin-16-10A1 (anti-B7-1, hamster IgG) (13) was the 
kind gift of Dr. Jeffrey Bluestone (University of Chicago, Chicago, 
IL). The CTLA4Igs and CD7 (CD7Ig) were produced as previ- 
ously described (8). FITC goat anti-rat Ig was selected for its min- 
imal staining of activated murine B cells and was obtained from 
Southern Biotechnology Associates, Inc. (Birmingham, AL). FITC 
mouse  anti-human  IgG Fc~/ was  purchased from Jackson  Im- 
munoResearch Laboratories,  Inc.  (West Grove, PA) and used for 
detecting the binding of CTLA4Ig. 2.4G2 (anti-FcR*/II)  (35) was 
generously provided by J. Titus (NIH). Equivalent results  were 
obtained when nonspecific staining by FITC goat anti-rat Ig was 
assessed either in the presence of aflinity-purified  normal rat IgG2a 
(Zymed Laboratories, Inc., South San Francisco, CA) or mAb 111/10 
(anti-goat Ig, rat IgG2a) (G. Laszlo, unpublished results).  FITC 
anti-Leu 4 and biotin-anti-Leu 4 were purchased from Becton Dick- 
inson Immunocytometry Systems (Mountain View, CA) and Texas- 
red-conjugated streptavidin (TRA) was purchased from Life Tech- 
nologies, Inc., BRL (Gaithersburg, MD). 
Flow Cytometry  (FCM).  FCM analysis was performed as previ- 
ously described (23) using a modified Dual-Laser FACStar Plus | 
(Becton Dickinson Immunocytometry Systems). Cells were stained 
at 4~  and washed in Hank's balanced salt solution containing 1% 
bovine serum albumin and 0.1% sodium azide.  To prevent non- 
specific binding of mAb via FcR interactions, 2.4G2 (35) was ei- 
ther added initially, when directly conjugated antibodies were used, 
or it was added after the FITC-conjugated goat anti-rat Ig or FITC 
mouse anti-human IgG Fc~ reagents. To prevent nonspecific binding 
of mAb to PEC, 10/~g of both normal rat IgG and 2.4G2 were 
added before the addition of the directly conjugated mAb. For two- 
color FCM analysis, cells were first stained with a saturating con- 
centration of culture supernatant or purified mAb, washed twice, 
and then incubated with FITC-conjugated antibodies.  Cells were 
then washed, and incubated with biotinylated mAbs. The antibody- 
labeled cells were washed before incubation with TRA. 
In some experiments, one-color profiles of FITC staining were 
generated by electronically gating  on  B220 §  B  cells,  CDllb/ 
MAC1 + PEC, or CD4 + or CD8 + T cells. To allow direct com- 
parison of staining intensities, values of median channel logarithmic 
fluorescence for the gated cell populations were converted to linear 
units using an empirically derived standard calibration curve for 
the logarithmic amplifier used. In the results presented in this re- 
port, values of background fluorescence have been subtracted after 
conversion to linear units. 
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previously (15). Briefly, 106 cells were preincubated for 30 rain at 
4~  with titrated amounts of the inhibiting mAb. 0.008 #g of 
CTLAIg was added and the cells were incubated for an additional 
30 min at 4~  in the presence of both the inhibiting mAb and 
CTLA4Ig. The cells were washed to remove unbound reagents 
and incubated with FITC mouse anti-human  IgG Fc7 to assess 
CTLA4Ig binding. After converting median channel logarithmic 
fluorescence to revolts and subtracting values of  background fluores- 
cence, percent inhibition in CTLA4Ig binding was calculated using 
the following formuh: [(uninhibited CTLA4Ig staining  -  inhibited 
CTLA4Ig staining)/uninhibited CTLA4Ig staining]  x  100%. 
Cytokine Assays.  Supernatants generated in the presence of 0.1% 
7D4 ascites (anti-Ib2Rc~ mAb), added to prevent II.r2 consump- 
tion (36), were analyzed for routine Ib2 and IFN-7 using ELISA 
kits purchased from Endogen Inc. (Boston, MA) and Genzyme 
Corp.  (Cambridge,  MA),  respectively. 
Polyraerase Chain Reaction (PCR).  RNA preparation and sub- 
sequent cDNA synthesis and amplification by PCR was performed 
as previously described (37, 38). Oligonucleotide primers specific 
for Ib2 were prepared by David Winkler (NIH) using an auto- 
mated DNA synthesizer (DuPont, Newtown,  CT) and purified 
by Sephadex G-50 column chromatography. Primers for IL-2 were: 
(sense)  5'  TCCACTTCAAGCTCTACAG 3'  and  (antisense)  5' 
GAGTCAAATCCAGAACATGCC 3'. Primers for hypoxanthine- 
guanine phosphoribosyl transferase (HPRT) were: (sense) 5' GAT- 
TCAACTTGCGCTCATCTTAGGC 3' and (antisense)  5' GTT- 
GGATACAGGCCAGACTTTGTTG 3' (39). 
cDNA  samples  were subjected to amplification using  a pro- 
grammed thermal cycler (Perkin-Elmer Cetus, Norwalk, CT). The 
optimum number of cycles was determined experimentally and was 
defined as that number of cycles that could achieve a detectable 
concentration that was well below saturating conditions.  Each cycle 
consisted of denaturation at 94~  for 1 min, annealing at 55~ 
for 1 min, and polymerization at 72~  for 2 rain. To verify that 
equal amounts of RNA were added in each PCR reaction within 
an experiment, mRNA for the "housekeeping gene;' HPRT, was 
also amplified by reverse transcriptase PCR.  20-#1 samples were 
resolved on 1.8% agarose gels in 0.5% Tris-buffered EGTA (TBE), 
run at 200 V, stained with ethidium bromide, and transferred to 
HybondTM-N + (Amersham Corp., Arlington Heights, IL) for 
analysis by Southern blotting. The membranes were prehybridized 
for 1 h in QuikHyb solution (Stratagene,  La Jolla, CA) and were 
then hybridized to 3zp-labeled oligonucleotide probes specific for 
either  Ib2  or  HPRT.  Oligonucleotide probe  for IL-2 was:  5' 
CTCCCCAGGAW_,CTCACCTTC 3' (256-277). Oligonucleotide 
probe for HPRT was: 5' GTTGTTGGATA_W~CCTTGAC  3' (39). 
Membrane-bound cDNA was hybridized overnight at 49~  After 
hybridization,  blots  were  washed  twice  for  15  rain  in  6x 
NaC1/NaH2PO4/EDTA (SSPE), 0.1% SDS at room temperature 
and then 5 rain at 45~  in 2x  SSPE, 0.1% SDS. Autoradiography 
was performed using Phosphor Screens (Molecular Dynamics Inc., 
Sunnyvale, CA) and exposed screens were scanned on a Phospho- 
imager (Molecular Dynamics Inc.). Relative scanning values for 
IL-2 are presented after normalizing to HPRT values. 
Results 
The GL1 mAb identifies B7-2, a CTLA4 ligand distinct 
from B7-1,  that can serve as a costimulatory molecule for 
T cell activation (15-17). Previous studies have shown B7-1 
expression by activated B cells (11, 20, 40-42), macrophages 
(13,  25),  dendritic cells  (43,  44),  and selected populations 
of activated T  cells (45,  46). It was therefore of interest to 
analyze the cell types expressing B7-2 and the activation con- 
ditions required for the expression of these two costimula- 
tory molecules. 
Expression of BT-1 and B7-2 by B Cells.  B7-2 expression 
was first examined on unstimulated B cells or on B cells stimu- 
lated with a variety of B cell-specific stimuli. Previous reports 
have failed to detect B7-1 expression on unstimulated B cells 
and have reported that LPS-stimulation or cross-linking of 
MHC class II or surface Ig induced low levels of expression 
of this costimulatory molecule (32, 40,  41).  In contrast, a 
low level of B7-2 expression was detected on freshly explanted 
B cells and expression was substantially increased by LPS-, 
anti-IgD-dextran, or IL-5 stimulation (Fig.  1). The B220 l~ 
subpopulation  of IL-5-stimulated  B  cells  analyzed in  the 
present study (Fig.  1 D) has previously been shown to be 
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Figure  1.  Expression  of BT-2 on unstimulated (A), LPS- (B), anti-lgD- 
dextran (C), or B220  ao Ib5-stimulated (D) DBA/2 B cells. All stimulated 
B cells were cultured for 2.5 d. These one-color FCM profiles were ob- 
tained by electronically  gating on all B220  § B cells (A-C) or on B2201~ 
IL-5-stimulated  B cells (D) and show B7-2 (mAb GL1)  expression (  ) 
or control (mAb Leu4) (  .... ) staining on these populations. The x-axis 
represents log green fluorescence  and the y-axis indicates the number of 
cells detected  at a given fluorescence  intensity. The numbers in parentheses 
indicate the mean fluorescence  intensity (mV) after the values for control 
staining were subtracted. 
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Figure 2.  Kinetics  of  CTLA41gbinding  and 
expression of the costimuhtory  molecules,  B7-1 
and B7-2. Cells were first incubated  with un- 
conjugated  rat mAbs  or fusion  proteins  and sub- 
sequently  stained  with either  goat anti-rat Ig- 
FITC  (for  B7-1 and B7-2) or mouse  anti-human 
FclgG-FITC  (for  CTLA4Ig);  B cells  were  iden- 
tiffed by counter-staining with  anti-B220. 
Values of median  channel  logarithmic  fluores- 
cence (green) were generated  by electronically 
gating on B220  + ceils  and converted  to linear 
units (mV) using an empirically  derived for- 
mula. Values of background fluorescence  ob- 
tained  by staining  with control  rat mAb or con- 
trol fusion  protein have been subtracted  after 
conversion  to mV and are plotted  on the y-axis. 
A depicts the relative staining intensities of 
B10.A B cells stimulated  with LPS for 0, 6, 
18, 36, or 60 h and analyzed  for the expression 
of  B7-1 (mAb 1G10) (,"l), B7-2 (mAb  GL1) 
([]-[~),  or CTLA4Ig binding (<>-~).  B 
depicts the  relative staining intensities of 
DBA/2 B cells stimulated  with anti-IgD-dex- 
tran for 0, 18, 36, or 60 h and analyzed  for 
the expression of B7-1 (mAb 1G10) (ll-m), 
B7-2  (mAb GL1) ([]-[~),  or  CTLA4Ig 
binding (~-O). 
the proliferating and Ig-secreting subpopulation of B cells 
present in IL-5-stimulated cultures (47).  B cells stimulated 
with LPS or anti-IgD-dextran also expressed B7-1, although 
the intensity of B7-1  staining was much lower than B7-2 
staining (Fig.  2). 
The relative contributions of B7-1 and B7-2 to costimula- 
tion of T  cells is an issue of substantial importance. It has 
been proposed that B7-1 and B7-2 are expressed/induced  with 
differing kinetics and thus, may play different roles in initi- 
ating and maintaining immune response  (17). To test this 
possibility, we analyzed the kinetics of induction of B7-1 and 
B7-2 expression  and CTLA4Ig binding on B cells activated 
in vitro by either LPS or anti-IgD-dextran (Fig. 2). Freshly 
explanted B cells expressed low levels of B7-2  (Fig.  1) and 
undetectable levds of B7-1 (40-42, and data not shown). 4-6 h 
after stimulation with either LPS or anti-IgD-dextran, in- 
creased expression  of B7-2  was routinely detected; expres- 
sion of B7-1 and CTLA4Ig binding were variably detected 
at this early time point. It should be noted, however,  that 
B7-2  staining was  "~10-fold brighter  than B7-1  staining; 
therefore, the ability to detect B7-2 before B7-1 may simply 
reflect the limits of detection by FCM analysis. Peak expres- 
sion of  both B7-1 and B7-2 occurred after 18-42 h of culture 
as did CTLA4Ig binding. By 60 h of stimulation B7-1, B7-2, 
and CTLA4Ig binding decreased in both stimulated B cell 
populations. B7-1 and B7-2 expression was not analyzed be- 
yond 60 h of culture since cell viability and recovery were 
substantially reduced. Thus, for these B cell stimuli, B7-2 
was detected earlier and at higher levels than B7-1, but there 
was no consistent difference in the kinetics of maximum ex- 
pression  of B7-1  and B7-2. 
Although B cells stimulated with LPS or anti-IgD-dextran 
expressed both B7-1 and B7-2, the intensity orB7-1 staining 
was much lower than B7-2 staining, even when analyzed by 
indirect immunofluorescence  with isotype-matched anti-B7-1 
and anti-B7-2 mAb. Moreover,  CTLA4Ig binding to these 
B  cells was essentially completely inhibited by GL1 mAb 
(specific for B7-2), with little or no inhibition observed with 
either of two B7-1-specific  mAb available (15). The failure 
to observe  significant inhibition by B7-1 mAb under these 
B7-1 mAb (16-10A1', 
B7-1 (r~  1Q10) 
B7-2 (mAb  GL1) 
BT-I (nl/~ 16-10A1) 
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B7-2 (rr~b GL1) 
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120 
B 
B7-1 -transfected 
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Figure 3.  Inhibition  of CTLA4Ig  binding  to 60-h LPS-activated  B cells 
(A) or B7-1-transfected  CHO cells  (B). Cells  were  preincubated  with 3/zg 
of either of two B7-1-specific  mAb (16-10A1 or 1G10) or anti-B7-2 mAb 
(GL1), followed  by incubation  with CTLA4Ig  or control CD71g. Cells 
were washed and incubated  with FITC mouse anti-human IgG Fc3' to 
detect bound  CTLA4Ig.  Percent  inhibition  of CTLA41g  binding  was cal- 
culated as described in Materials and Methods. 
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pete with  CTLA4Ig for binding  since either of two B7- 
1-specific mAb (16-10A1 or 1G10) efficiently  blocked binding 
of  CTLA4Ig to B7-1-transfected (B7-2-negative) CHO cells 
(Fig.  3). Taken together these results indicate that activated 
B cells express quantitatively higher amounts of B7-2 than 
B7-1. 
An early but transient increase in B7-2 expression (begin- 
ning 4-6 h after culture) also occurred on B cells that were 
cultured in vitro in the absence of defined B cell stimuli. After 
overnight culture B7-2 staining returned nearly to the level 
originally detected on freshly explanted B cells. Both this tran- 
sient increase in B7-2 expression as well as the increase in- 
duced by LPS-stimulation were completely inhibited by cy- 
cloheximide (data not shown). 
Expression of B7-1 and B7-2 by Activated Macrophages.  We 
next examined macrophages for the expression of B7-1 and 
B7-2 costimulatory molecules. Freshly explanted MAC-1 + 
thioglycollate-induced macrophages (PEC) (>80% latex in- 
gesting) expressed both B7-1 and B7-2 (Table 1). Expression 
of both B7-1 and B7-2 was modestly increased on PEC cul- 
tured in vitro for 18 h in medium alone. Further, LPS stimu- 
lation of PEC induced substantial increases in the expression 
of both molecules. In contrast to the increased expression 
of  both B7-1 and B7-2 on LPS-stimulated PEC, IFN-'y stim- 
Table  1.  Expression of B7-I and B7-2 Molecules on 
Thioglycollate-induced Perito.eal Macrophages Stimulated with 
either LPS or IFN-~ 
B7-1'  B7-2s 
PEC cell  Percent  Percent 
culture*  mVll  change  I  mV  change 
Uncultured  545  -  173  - 
Cultured/ 
medium  629  + 15  369  + 113 
Cultured/ 
LPS  725  + 33  725  + 319 
Cultured/ 
IFN-7  425  - 22  611  + 253 
* PEC were incubated for 18 h with media, LPS (15 #g/ml) or IFN-'y 
(100 U/ml). 
B7-1 expression  was detected  using biotin-conjugated 16-10A1 mAb. 
Differences in fluorescence  intensity  between  B7-1- and B7-2-specific  stain- 
ing may reflect  differences  in the amount of  biotin conjugated  rather than 
actual differences  in the number of B7-1 and B7-2 molecules  expressed. 
S  B7-2 expression was detected using biotin-conjugated GL1 mAb. 
II One-color  profiles of TRA staining with either  biotin anti-B7-1 or bi- 
otin anti-B7-2  were generated  by electronically  gating on MAC1  + PEC. 
The numbers in this experiment  indicate the mean fluorescence  intensity 
(mV) for MAC1  + cells after the values for control staining were sub- 
tracted. 
I Percent  change in fluorescence  was calculated using the following  for- 
mula: [uncultured  (mV) -  cultured (mV)]/uncuhured  (mV) x  100%. 
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ulation resulted in differential effects on B7-1 and B7-2 ex- 
pression. Relative to expression levels observed on freshly ex- 
planted or control cultured PEC, B7-2 expression was increased 
by in vitro stimulation with IFN-% whereas B7-1 expres- 
sion was decreased by the same IFN-7 stimulation. Due to 
technical constraints, B7-1 and B7-2 expression on PEC was 
analyzed using directly conjugated antibodies; therefore, differ- 
ences in fluorescence intensities observed using these two mAbs 
may reflect differences in efficiency of biotinylafion rather than 
differences in the expression of B7-1 and B7-2. Thus, expres- 
sion of the costimulatory molecules of B7-1 and B7-2, was 
influenced by activation stimuli and,  strikingly,  these two 
costimulatory molecules are subject to independent regulation. 
Expression of BT-2 by T  Cells.  B7-2 expression was next 
investigated on T cells. As can be seen in Fig.  4, freshly ex- 
planted spleen T  cells expressed a low, but detectable level 
orB7-2. After stimulation with soluble anti-CD3e for 18 h, 
both CD4 + and CD8 + T cells showed increased expression 
orB7-2. Similar results were obtained when T cells were stimu- 
lated with Concanavalin A (data not shown). Kinetics of  peak 
expression of B7-2 by activated T cells were similar to those 
observed for activated B cells (data not shown). In contrast 
to the low level expression of B7-2 on freshly explanted pe- 
ripheral T cells, B7-2 was undetectable on freshly explanted 
thymic T  cells  (data not  shown). 
Participation orB7-1 and B7-2 Molecules in T  Cell Prolifera- 
tion to MIP Stimulation.  Since both B7-1 and B7-2 mole- 
cules have been shown to provide costimulatory signals  for 
T cell activation, experiments were performed to analyze their 
individual and joint contributions to costimulatory function. 
In these experiments, BALB/c (Mls'-reactive) T  cells were 
stimulated with BALB.Mls~-positive  APCs in the presence 
or absence of inhibitory mAb specific for B7-1 or B7-2 or 
with CTLA4Ig (Fig. 5). The proliferative response of BALB/c 
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Figure 4.  Expression  of B7-2 on freshly  explanted (.4 and C) or anti- 
CD3e-stimulated (B and D) BALB/c T cells. T cells were cultured for 
1.5 d in the presence  of soluble anti-CD3e and APCs. These one-color 
FCM profiles  were obtained  by electronically  gating on CD4 + T cells (-4 
and B) or on CD8 + T cells (C and D) and show B7-2 (mAb GL1) ex- 
pression (  ) or control (mAb Leu4) (  .... ) staining on these  popu- 
lations. The numbers  in parentheses  indicate  the mean fluorescence  inten- 
sity (mV) after the values for control staining were subtracted. Figure 5.  Inhibition  of the proliferative  response  of  BALB/c 
T cells to Mls~  by B7-1- and B7-2-specific mAb. A depicts 
the percent inhibition  of T cell proliferation observed when 
2  x  10s BALB/c T cells were stimulated with 10  s mitomycin 
C-treated APC and the indicated concentrations of  test mAb: 
anti-B7-2 (GL1 mAb) (*-*), anti-B7-2 mAb  +  10 #g/ml 
anti-B7-1 (1G10 mAb) (O-0),  anti-B7-2 mAb +  5/zg/ml 
anti-B7-1 mAb (O-Q), anti-B7-2 mAb +  1 #g/ml anti-B7-1 
mAb (A-A). B  depicts  the percent  inhibition of T  call 
proliferation by titrated amounts of CTLA4Ig: 5 #g/ml (~), 
0.5/Lg/ml (1~), or 0.05 #g/m1 (D). Control isotype matched 
mAb (mAb III/10) was used at 10 #g/ml (roll);  5 #g/ml con- 
trol CD7Ig generated  -10% inhibition (data not shown). 
Cultures were pulsed at 72 h and harvested at 84 h. T cells 
cultured without APC generated 147 cpm. T cells cultured 
with BALB/c.Mls~ APC and no inhibitory mAb generated 
132,217 cpm and T  cells cultured with syngeneic BALB/c 
APC generated 175 cpm. Percent inhibition was calculated 
using the following formuh: [uninhibited  (cpm) -  inhibited 
(cpm)]/uninhibited (cpm)  x  100%. 
T cells to Mls" superantigen  was only minimally affected by 
anti-B7-1 mAb alone, whereas blocking of B7-2 resulted in 
profound inhibition, comparable  with that observed with 
CTLA4Ig. Further, adding B7-1 and B7-2 mAb produced 
little to no increase in inhibition over what was seen when 
B7-2 was added alone. This result suggests that B7-2 is the 
major costimulatory molecule involved in the activation of 
T  cells by Mls  ￿9  presented  by this  anti-IgD-activated APC 
population. 
Inhibition of B7-1 and B7-2 Costiraulatory Pathways Blocks 
T  Cell Proliferation and Cytokine Production but Not the Induc- 
tion of CD69 and IL.2Rc~.  To further define the contribu- 
tion(s) of B7-1 and B7-2 costimulatory molecules to antigen- 
specific T  cell activation,  Va8.1  Tg (Mls'-reactive)  T  cells 
were stimulated with Miss-expressing CBA/J APCs in the 
presence or absence of inhibitory mAb specific for B7-2 or 
LFA-1.  Parallel cultures  were  analyzed  for  proliferation, 
cytokine production, or CD69, and IL-2Rc~ expression. T 
cell proliferation was substantially inhibited by the addition 
of anti-B7-2 (GL1 mAb) (63% inhibition) and almost com- 
pletely inhibited by the addition of anti-LFA-1 (FD441.8 mAb) 
(99% inhibition) (Table 2). Supernatants  were generated in 
parallel cultures and analyzed by ELISA for secreted cytokines 
and by PCR for mRNA expression of the T cell cytokines 
IL-2 and IFN-3,. Anti-B7-2 mAb substantially inhibited IL-2 
and IFN-3, generation whereas anti-LFA-1 mAb almost com- 
pletely inhibited the production of these cytokines (Fig. 6). 
Induction of IL-2 and IFN-'), responses was investigated fur- 
ther by PCR analysis. The induction of IL-2 mRNA (Fig. 
7) and IFN-y mRNA (data not shown) was inhibited in a 
pattern similar to that observed for assays of secreted cytokine. 
This result suggests that the inhibition of proliferation that 
occurs in the presence ofmAb to B7-2 or LFA-1 may be due, 
at least in part, to reduced IL-2 production. In contrast  to 
the inhibitory effects of GL1 mAb on T  cell proliferation 
and cytokine production, blocking the costimulatory signal 
Table  2.  Comparative Effects of mAb Specific  for B7-2 and LFA-1  on Proliferation and Expression of CD69 and IL-2Rcx Antigens 
by  V~8.1 Tg  T  Cells in Response to MIP 
Cell culture*  Response 
V08.1  Percent  Percent 
T  APC  Mls  ~  Inhibitor~  Proliferations  CD69LL  IL-2Ro~ 
+  CBA/J  +  control IgG2a  193,527  29  32 
+  CBA/J  +  B7-2  71,899  30  29 
+  CBA/J  +  LFA-1  2,158  5  5 
+  CBA/CaH  -  -  831  3  0 
* T cells were prepared by passage over plates coated with rabbit-anti-mouse  Ig. APCs were prepared by T depletion of spleen cells harvested from 
mice that had been injected with goat anti-IgD serum and were inactivated  by treatment with mitomycin C. 
All mAbs were used at  a final concentration of 1 /*g/ml. 
S Cultures were pulsed during the last  15 h of a 60-h assay with 1/~Ci 3H. T  cells cultured without any APCs generated  1,084 cpm. 
U  Cells were cultured for 18 h  and analyzed by two-color  FCM analysis for CD4 expression and either CD69 or IL-2R~ expression. The results 
shown here are presented  as the percent  of CD4 + T  cells that are CD69 + or IL-2Ro~+. 
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Figure 6.  Effect  of  B7-2-specific  mAb  and  LFA- 
1-specific mAb on II.-2 and IFN-'y induction by Va8.1 
Tg T calls in response to Mls'. Supernatants  were gener- 
ated in the presence of 0.1%  7D4 ascites and harvested 
at the indicated times. A shows IL-2 production (pg/ml) 
for VaS.1  Tg T  cells  stimulated with  Miss-expressing 
CBA/J APC and cultured in the presence of control rat 
IgG2a  mAb  (III/10)  (I-1-/-1),  anti-B7-2  mAb  (GL1) 
(ll-I),  or anti-LFA-1  mAb  (F44.1)  (X-X).  B  shows 
IFN-3, production (pg/ml) for Va8.1 Tg T calls stimu- 
hted with Mls'-expressing CBA/J APC and cultured in 
the presence of control rat IgG2a mAb (D-FI), anti-B7- 
2 mAb (11-11), or anti-LFA-1 mAb (X-X). V~8.1 Tg T 
cells cultured without  APC or stimulated with Mls'- 
negative CBA/Ca APC produced undetectable amounts 
of both IL-2 and IFN-3,. All mAb were used at a final 
concentration of 1 #g/ml that was previously shown to 
provide maximum inhibitory effect. 
provided by B7-2 did not significantly inhibit the percent 
of CD4 + T cells induced to express CD69 or IL-2Rot (Table 
2) nor the fluorescence intensity of the induced activation 
antigens (data not shown). Anti-LFA-1 mAb completely in- 
hibited the induction of these activation antigens. Blocking 
with either B7-1 mAb alone or with a mixture of both B7-1- 
and B7-2-specific mAb also failed to inhibit the induction 
of these activation antigens (data not shown). Similar results 
were obtained when T cells were stimulated by soluble anti- 
CD3e under APC-dependent conditions (data not shown). 
Discussion 
The present study investigated the regulation of expres- 
sion orB7-1 and B7-2 costimulatory molecules and analyzed 
their contribution to costimulatory function under selected 
conditions. Low levels of BT-2 were expressed by freshly ex- 
planted B and T cells and expression was substantially in- 
creased by a variety of T and B cell-specific stimuli. Analysis 
of  B7-1 and B7-2 induction on B cells stimulated with either 
LPS or anti-IgD-dextran revealed a similar kinetics of peak 
expression for both molecules that occurred after 18-42 h 
of  culture. Thioglycollate-induced PEC expressed both B7-1 
and B7-2 molecules, and LPS stimulation resulted in increased 
expression of  both of these costimulatory molecules. In con- 
trast, B7-1 and B7-2 were differentially regulated in vitro in 
response to IFN-3'; B7-2 expression was increased while B7-1 
expression was decreased on these PEC.  In addition,  B7-2 
as well as B7-1 are expressed on dendritic cell populations 
(reference 47a and R. Steinman, personal communication). 
Thus, B7-1 and B7-2 are expressed on a broad spectrum of 
lymphocytes,  including B cells, T  cells, macrophages,  and 
dendritic cells. 
The contribution of costimulatory signals to in vitro T 
cell activation was analyzed by assessing the effects of B7-1, 
B7-2, and LFA-1 on T cell activation to Mls  a. These results 
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Figure 7.  PCR analysis of the effect of B7- 
2-specific mAb and LFA-l-specific mAb on IL-2 
mRNA generation by V~8.1 Tg T cells in re- 
sponse  to  Mls'-expressing APCs.  Cultures 
were harvested at the indicated times, mRNA 
was isolated,  and  the resulting cDNA was 
amplified in the presence of Ib2-spedfic oli- 
gonucleotide primers (24  cycles) or HPRT- 
specific  oligonudeotide primers. PCR-amplified 
products were resolved on agarose gels, trans- 
ferred to nylon membrane,  and subjected  to 
Southern analysis with either 3ZP-labeled II: 
2-specific  or  HPRT-specific  oligonucleotide 
probes. Autoradiography was performed using 
Phosphor screens and analyzed using a Phos- 
phoimager (Molecular Dynamics, Inc.).  The 
scanning  values for IIr2 were normalized to 
HPRT values and are plotted on the y-axis. 
These results depict relative IL-2 mRNA expression on V~8.1 Tg T cells stimulated with Miss-expressing CBA/J APC and cultured in the presence 
of control rat IgG2a mAb (III/10) (O-O),  anti-B7-2 mAb (GL1) (D-I-I), or anti-LFA-1 mAb (F44.1) (O-O). V~8.1 Tg T cells cultured without 
APC or stimulated with Mls'-negative CBA/Ca APC expressed undetectable I1:2. All mAb were used at a final concentration of I #g/ml that was 
previously shown to provide maximum inhibitory effect. 
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IgD-activated B cell-enriched splenocytes was highly depen- 
dent on costimulatory function of B7-2 with little evidence 
for a role of B7-1. Further, inhibition of either B7-2 or LFA-1 
interactions inhibited not only antigen-induced T cell prolifer- 
ation but also IL-2 and IFN-'t mRNA and protein produc- 
tion. Addition of B7-2 mAb failed to inhibit induction of 
early T cell activation antigens CD69 and IL-2Rct whereas 
LFA-l-specific mAb completely inhibited the induction of 
these antigens. 
The potential for signaling through the B7:CD28:CTLA4 
costimulatory pathway is more complex than had previously 
been  appreciated.  Thus,  T  cells can express  at  least  two 
receptors  for costimulation, CD28 and CTLA4 (2,  7, 48, 
49), and APC can express at least two and perhaps more (15, 
19, 50-53) molecules capable of interacting with one or both 
of these receptors on the T cell. It is not yet clear whether 
different  costimulatory molecules such as B7-1  and B7-2 
mediate distinct function in the course of immune responses. 
It has been proposed that B7-1 and B7-2 are expressed with 
different kinetics and thus may play different roles in initi- 
ating or maintaining immune responses (17). For this reason, 
we examined the kinetics of induction and the cellular distri- 
bution of B7-1 and B7-2 after stimulation. These experiments 
demonstrated that B7-2 was detected earlier than B7-1 on 
LPS- or anti-IgD-dextran-activated B cells and that B7-2 may 
be expressed at higher levels than B7-1; however, the kinetics 
of peak expression of these two costimulatory molecules was, 
in fact, not different. Further, since these experiments were 
performed using isotype matched mAb (rat IgG2a) and goat 
anti-rat Ig FITC, the 10-fold difference in fluorescence in- 
tensity of B7-1 and B7-2 staining may reflect the relative differ- 
ence in the numbers of B7-1 and B7-2 molecules expressed 
by these B cell populations. Consistent with this interpreta- 
tion,  B7-2-specific  mAb  completely inhibited  CTLA4Ig 
binding by all B cell populations tested, with little or no 
inhibition observed with either of two B7-1-specific mAb 
available The low level of staining observed on B cells using 
B7-1-specific mAb and the failure of B7-1-specific mAb to 
inhibit CTLA4Ig binding to B cells were not due to lower 
affinities of these mAb since either of two B7-1-specific mAb 
(16-10A1 or 1G10) effectively inhibited the binding CTLA4Ig 
to B7-1-transfected CHO cells. Thus, quantitative differences 
in the amount of B7-1 and B7-2 expressed on activated B 
cells may profoundly influence their contribution to costimula- 
tory function(s). The possibility remains, however, that dis- 
tinct stimuli, including physiologically relevant signals, may 
result in kinetics and relative expression  of B7-1 and B7-2 
that differ from the patterns described  here. 
It is of considerable  interest to identify the biologically 
relevant signals, mediated either by soluble cytokines or by 
cell contact, that can regulate B7-1 and B7-2 expression. Nabavi 
et al. (32) recently reported that induction orB7 (B7-1) could 
be mediated by signaling through MHC class II molecules 
on the APC.  In the present report we demonstrated that 
cytokines such as IL-5 and IFN-'y, were able to regulate the 
expression of costimulatory molecules. The observation that 
the expression of B7-1 and B7-2 on PEC is differentially regu- 
lated by IFN-y stimulation further suggests that the costimula- 
tory function mediated by these two molecules can be regu- 
lated differentially as well. Recently Larsen et al. (47a) emunined 
B7-1 and B7-2 expression and costimulatory function of splenic 
dendritic cells cultured with either GM-CSF or IFN-'y and 
showed that GM-CSF-stimulation increased expression of both 
B7-1 and B7-2 molecules whereas IFNo,-stimulation resulted 
in increased expression of B7-2 and decreased expression of 
B7-1. Further analysis of the relative contributions of cell con- 
tact and cytokine-mediated signals to the regulation of B7-1 
and B7-2 expression and costimulatory function will be crit- 
ical to an overall understanding of the roles played by these 
molecules. 
At the current time, it is not known whether B7-1 and 
B7-2 mediate distinct or overlapping costimulatory functions. 
Several lines of experimental evidence suggest that the co- 
stimulatory signals provided by B7-1 and B7-2 may be,  at 
least in part, redundant. It has been demonstrated that trans- 
fected cells expressing high amounts of either B7-1 or B7-2 
can provide costimulatory function (6, 12, 17). Similarly, APCs 
derived from mice in which the B7-1 gene was inactivated 
by homologous recombination express B7-2 and not B7-1, 
and are competent APCs (16). Thus, either B7-1  or B7-2 
is sufficient,  in the absence of the other, to provide some 
costimulatory function. In systems that have examined the 
costimulatory function of normal human and murine APCs, 
presumably capable of expressing both B7-1 and B7-2, the 
contribution of each is not so dear. For example, Razi-Wolf 
et al. (13) have shown that T cell prolif~ation to Concanavalin 
A or alloantigen stimulation was dependent on expression 
of B7-1 as evidenced by essentially complete inhibition with 
anti-B7-1 mAb. In contrast, our experiments demonstrated 
that  T  cell  proliferation  to  Mls'  expressing  APC  or  to 
soluble anti-CD3 (15) presented by activated B cell popula- 
tions was highly dependent upon B7-2 with little if any de- 
pendence on B7-1. The explanation for these results may in- 
volve the stimuli studied as well as the APC populations used. 
Tha contributions of B7-1, B7-2, and LFA-1 to T cell ac- 
tivation were further characterized  by analyzing in parallel 
several parameters of T cell activation.  Blocking of the B7-2 
costimulatory pathway on APC capable of expressing both 
B7-1  and B7-2  resulted in a profound reduction in T  cell 
proliferation and in IL-2 and IFN-3, production but had no 
effect on the induction of the T cell activation antigens CD69 
and IL-2P,  c~. In contrast, anti-LFA-1 mAb inhibited T cell 
proliferation, cytokine production, and induction of activa- 
tion antigens. These results are consistent with a model in 
which blocking LFA-1/ligand interactions prevents  TCR- 
mediated signaling events that are necessary for all of the mea- 
sured components of T  cell activation,  whereas inhibition 
of B7-2 allowed TCR-mediated signaling events to occur (as 
evidenced by the induction of CD69 and IL-2Rct expression) 
but inhibited the distinct costimulatory signal(s) that are neces- 
sary for optimal cytokine production and cytokine-dependent 
proliferation. This interpretation is consistent with the previous 
demonstration that, in the presence of TCR signals, CD28 
signaling plays a critical role in T cell cytokine production 
and mRNA stabilization  (54-56). 
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